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the theoretical framework to guide the focus group discussions. Each session was 
audio-recorded, transcribed, and participant responses were analyzed for qualita-
tive content. Results: Two, 60 minute focus groups (Total N= 12) were conducted. 
Time constraints and privacy issues presented as major themes in the discussions. 
Regarding advantages/disadvantages, participants emphasized the importance of 
counseling for the discussion of potential drug interactions and side effects of their 
medications and felt that their doctor would approve of them speaking with a 
pharmacist about their medications. However, both patient and pharmacist’ time 
constraints presented as a barrier to counseling. The majority of participants also 
stated that they would receive counseling more readily if it were provided in a 
more private environment. Only one participant was aware of MTM services and 
medication counseling requirements by law, however the majority stated that if they 
were aware of this mandate they would more readily accept pharmacist provided 
counseling. ConClusions: The identification of barriers to pharmacist provided 
counseling, specifically privacy and time limitations, may be beneficial for creating 
specific interventions that would increase patients’ intentions to receive pharmacist 
provided counseling.
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objeCtives: Describe the state of CER, its use and impact on medical decision-mak-
ing, and perceptions about the future for CER, application of evidence, and impact 
of CER Methods: Internet and mail survey of health care stakeholders, including 
government, health plans, researchers, human resources specialists, employers, and 
trade organizations, that are influential in or affected by CER; telephone follow-up 
to maximize response. Results: The 2014 survey, the fourth in a series begun in 
2010, found that health care stakeholders recognize the importance of CER but con-
tinue to believe, as in previous surveys, that significant impact of CER on treatment 
decisions is still in the future. PCORI is now recognized by most stakeholders as a 
leading organization in establishing research priorities, funding and monitoring 
research, and translating and disseminating the research. The 2014 survey indicates 
a clear need for more and better evidence. Only five percent of respondents believe 
the evidence base is sufficient to inform treatment decisions, and just 10 percent 
indicate that real-world evidence is being used to support decision-making. About 
15 percent of stakeholders indicated that variability in individual patient treatment 
response in being widely considered in treatment decisions. ConClusions: The 
2014 survey indicates continued belief among stakeholders that CER is important 
to them, but the most significant impacts are yet to be felt. The environment for 
CER is changing, and PCORI is recognized as a key organization in the spectrum of 
activities related to CER. The evidence base is not sufficiently complete to inform 
treatment decisions, and the influence of real-world evidence and variability in 
patient response are not yet apparent and warrant monitoring.
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objeCtives: We assessed the prevalence of shortages of drugs approved for orphan 
indications and evaluated the characteristics of the orphan drugs reported in short 
supply in the US. Methods: Orphan approval data were collected from the US FDA 
webpage. Shortage data were provided by the Drug Information Service, University 
of Utah Hospitals and Clinics (UU). The prevalence of shortages was estimated as 
a percentage of the total number of orphan indications approved in the US as of 
September 25, 2013. Results: The FDA approved 449 orphan indications for 338 
products (66.0% molecular entities, 23.7% therapeutic biologics, and 10.4% other 
biologics). Injectable products represented 59.7%, oral products 30.7% and other 
9.6% of the orphan indications. The average number of orphan indications per year 
increased from 6.9 in 1983-1989 to 23.3 in 2010-2013. The UU listed 1,740 shortages 
in the period 2000-09/25/2013. A total of 146 (8.4%) of shortages were for products 
with orphan indications. Shortages were estimated to affect 28.5% of FDA approved 
orphan indications (128 shortages out of 449 orphan indications approved by the 
FDA), this included 36.0% of indications for molecular entities, 15.8% of for thera-
peutic biologics, and 6.7% for biologics. The average estimated duration of shortages 
was 252.1±322.1 days for drugs with orphan indications and 270.3±336.3 days for 
other drugs (differences not statistically significant). The reason for the shortage was 
unknown for 50.2% of the shortages. Drugs with orphan indications were signifi-
cantly more likely to have manufacturing problems as the reason for the shortage 
(67.6%) than other drugs (52.9%, p= 0.02). ConClusions: Over one-fourth of the 
drugs with approved orphan indications were reported in short supply in the US. 
Problems with manufacturing represented most of the reported causes of shortages. 
Additional research is needed to assess the risk factors, causes and clinical impact 
of orphan drug shortages.
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highest for PILs (p< 0.001). Interaction analyses revealed that for one-page formats; 
the information load reduces, information anxiety reduces and product knowledge 
increases to a greater extent in high involvement scenario. ConClusions: The 
PILs had significantly higher patient comprehension as compared to the current 
practice and text-only prototypes. Increasing involvement further improves product 
knowledge, intention to read and attitude towards leaflet. The FDA could consider 
these findings and provide guidelines to design a concise prescription drug infor-
mation leaflet to eventually improve the expected outcomes associated with these 
information sources.
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objeCtives: This study aims to evaluate safety culture dimensions among phar-
macists using Hospital Survey on Patient Safety Culture (HSOPSC) developed by 
AHRQ. Methods: We surveyed nationwide the situation of patient safety culture 
in 37 hospitals (18,960 persons) between 2011 and 2012FY, which were allowed 
for additional costs on patient safety countermeasures under the social insurance 
medical fee schedule in Japan. Results: We classified 37 hospitals into three groups 
by number of beds; A group’s bed number was 20 to 200 (six hospitals), B group’s was 
201 to 400 (twelve hospitals), and C group’s was more than 401 (19 hospitals). The 
overall response rate was 87.9% (16,670/18,960 persons). Number of respondents 
in A group was 996 (1,116 persons; response rate: 89.2%) including 19 pharmacists, 
number of respondents in B group was 3,319 (3,674 persons; response rate: 90.3%) 
including 100 pharmacists, and number of respondents in C group was 12,355 (14,170 
persons; response rate: 87.2%) including 340 pharmacists. The overall average posi-
tive response rate (RR) for the 12 patient safety dimensions of the HSOPSC was 
46.6% in A group, 52.7% in B group and 51.0% in C group. In terms of occupational 
categories, RRs for pharmacists were 48.3% in A, 56.8% in B and 50.0% in C, RRs for 
physicians were 44.3% in A, 52.9% in B and 50.7% in C, and RRs for nurses were 43.4% 
in A, 52.8% in B and 51.6% in C, in each. RR for pharmacists was the highest among 
these three professionals in A and B groups. In terms of pharmacists, RRs in B group 
was the highest among three groups. ConClusions: The HSOPSC measurement 
provides the evidence for assessment of patient safety culture for pharmacists in 
Japan’s hospitals. This result suggested that pharmacists might be highly concerned 
with patient safety in Japan.
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objeCtives: Spontaneous reporting of adverse drug events (ADEs) by pharmacists 
helps ensure safe medication use; an important aspect of pharmaceutical care. This 
systematic review summarizes published survey articles regarding determinants 
of ADE reporting by pharmacists Methods: A literature search was conducted to 
identify original survey articles regarding pharmacists’ knowledge, attitudes and 
demographic factors associated with frequency of ADE reporting. Search engines 
used included PubMed, CINHAL and Web of Science.For each survey article, the 
following data were extracted: pharmacists working setting, sample size, survey 
delivery, response rate, reporting rate, demographic factors, knowledge and atti-
tudes associated with reporting Results: Only 32 of the 820 articles identified 
met the study requirements. The number of respondents in the studies included 
in this review ranged from 20 to 643. Response rate ranged from 26.4% to 100%. Self 
– administered questionnaires were used in 47% (15/32) and 41% (13/32) surveyed 
both hospital and community pharmacists. A study of Canadian pharmacists found 
that 65% had reported an ADE, followed by 59% and 32% of pharmacists in the UK 
and the US respectively. Pharmacists were found to have favorable attitude toward 
reporting (7 studies).Years of work experience as pharmacist was associated with 
significantly increased ADE reporting in 2 studies. Pharmacists in hospital settings 
reported significantly more ADEs than pharmacists in community/retail settings 
(4 studies).Lack of knowledge of pharmacovigilance concepts, systems and/or the 
ADE reporting process were significant barriers to reporting among 72%; uncertainty 
that a specific drug is responsible for a particular ADE in 38%; and lack of time in 
34% of studies. The factor most frequently recommended to improve reporting was 
special training/education programs related to pharmacovigilance concepts and 
ADE reporting (16/32). ConClusions: To improve reporting of ADE by pharma-
cist, educational interventions to address gaps in knowledge and attitudes could 
be implemented within pharmacy curriculum or as part of continuing education.
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objeCtives: While pharmacist provided counseling has proven effective in posi-
tive patient drug outcomes, only between 40-67% of patients are receiving this 
service. As the pharmacy profession moves towards providing greater patient care 
services, patients’ intentions to receive pharmacist provided counseling are not 
well understood. The objectives were to elicit modal salient behavioral beliefs, 
normative referents and control beliefs of patients regarding receiving commu-
nity pharmacist’ provided counseling and determine the factors that influence 
intention to receive counseling (i.e. legal requirements and awareness of MTM 
services). Methods: Focus groups were conducted with a convenience sample of 
community-pharmacy patients in Houston, TX, using a semi-structured interview 
guide with 14 open-ended questions. The theory of planned behavior was used as 
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outcome, percentage of days in which all procedures were completed within the 
scheduled OR day, was higher in the OR using sugammadex (79.8%) compared to 
the OR using neostigmine (40.7%) [range for sugammadex values was 40.7% to 
93.1% in the exploratory analyses]. Base-case total overtime over a one-month 
period was less with sugammadex use compared to neostigmine use (3.6 and 15.0 
hours, respectively). ConClusions: Even relatively modest reductions in proce-
dure times with use of sugammadex for NMB reversal might lead to meaningful 
improvement in OR efficiency and reduced overtime.
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objeCtives: To determine the positive recommendation rate for combination 
drugs under the CDR. Methods: In Canada, eligible non-cancer prescription 
drugs approved by Health Canada (including combination drugs) are reviewed by 
the Common Drug Review (CDR) process that is part of the Canadian Agency for 
Drugs and Technologies in Health (CADTH). The CDR makes reimbursement rec-
ommendations that are considered by provincial and federal plans in making their 
formulary coverage decisions. The majority of the combination drugs consist of 
individual components that are currently available in the market. The advantages 
to combination drugs are several, including reduced dispensing fees, reduced pill 
burden and possibly synergistic effect. CDR-reviewed combination drugs in our 
proprietary CDR Tracker®database were analyzed. Results: 33 unique combina-
tion drugs with 36 submissions have been reviewed by the CDR. The positive rec-
ommendation (List; List in a similar manner; List with criteria; List with criteria/
condition) rate of these 36 submissions were 64% (23 of 36). This is higher than the 
average CDR positive recommendation rate for all drugs of 54%. ConClusions: 
The high positive recommendation rate for combination drugs may be reflective of 
the various clinical and economic advantages of this drug class.
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objeCtives: In addition to Canadian Drug Review (CDR), an independent, prov-
ince-driven mechanism is now in place known as Pan Canadian Pricing Alliance 
(pCPA). The purpose of this virtual committee is to conduct joint provincial / 
territorial negotiations for brand name drug products when appropriate. Since 
this initiative was announced by Premiers in August 2010, the implication of this 
initiative has yet to be measured. This paper quantifies the impact of pCPA by 
comparing the ‘days to listing’ and longitudinally assessing data between 2008 
and 2013. Methods: Using publically accessible CDR data, IMS Brogan applied 
selection criteria to identify drugs for analysis including: Tracked all drugs post 
CDR recommendation (made through 2008 – 2012) for a duration of 18 months, 
and the Used Ontario Public Drug Plan (OPDP), except Quebec, the leading province 
of listing new products in the Formulary, as a representative to measure time 
from CDR recommendation to formulary listing. Selection criteria were rigorous 
to ensure credible results; the resulting sample size was n= 103. If a drug was 
reviewed for multiple indications, it was given an additional weight based of the 
number of indications. Results: Findings revealed that, although pCPA is an 
added layer to the public listing in the Canadian health care system, time to listing 
has continued to decrease. The average time to listing for drugs reviewed in 2012 
was185 days, a 33% decrease compared to 2008. Further analysis assessed median 
and minimum days to listing, which further supported this trend. ConClusions: 
The recent trends show time to listing of new products on the OPDP Formulary 
has been decreasing; pCPA does not delay the listing process. Future trends could 
not be ascertained due to data horizon length.
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objeCtives: The objective of this study was to evaluate the decisions provided 
by the National Commission for Health Technology Incorporation (CONITEC) from 
the Brazilian public health care system (SUS) submitted from January 2011 until 
September 2013. Methods: All the submissions to CONITEC were evaluated based 
on the data available at the Ministry of Health website. The submissions were cat-
egorized by the type of submission (inclusion or exclusion), type of applicant (public 
body or external) and type of technology (drug, health product or procedure). The 
status of each submission requesting the incorporation of a new technology was 
analyzed and the success rate of the submissions was calculated as the number 
of incorporations divided by the number of submissions. Results: A total of 276 
submissions were done to CONITEC and 261 of those (95%) required the incorpora-
tion of a new health technology. Among the incorporation submissions, 64% were 
related to drugs, 20% to procedures and 16% to health products. Forty six per cent 
of those submissions were done by public bodies. The status of the submissions 
in September 2013 was: 56 positive decisions for incorporation (22%), 39 negative 
decisions (15%), 99 submissions under evaluation (38%), 55 submissions denied for 
failure to comply with CONITEC requirements (21%), 5 submissions terminated at 
the request of the company (1.9%), 6 submissions considered outside the scope 
of CONITEC (2.3%) and 1 technology already incorporated by SUS (0.4%). The suc-
cess rate of the submissions done by public bodies was 33% and 11% for external 
submissions. ConClusions: The rate of technologies incorporated by CONITEC 
was higher than the rate of negative decisions but the success rate is still limited. 
Most submissions are still under evaluation and the rate of submissions considered 
incompliant was high, showing that there’s a learning process to comply with the 
new CONITEC requirements.
objeCtives: Disease-related malnutrition (DRM) is not confined to develop-
ing countries and remains a significant cause of diseases and deaths worldwide. 
Present in all health care settings DRM is often unrecognized and untreated. Despite 
information on DRM prevalence and clinical outcomes, there is comparatively lit-
tle information on its economic impact. This study reviewed the assessment of 
DRM and associated economic burden in different geographic regions. Methods: 
A comprehensive literature review was undertaken for all publications from 1998 
to July 2013 using Medline, EMBASE, Cochrane, HEED databases. Search completed 
for English and non-English (German, Spanish, Italian, French, and Arabic) articles. 
Articles were systematically selected if they presented data for hospitalized patients 
on at least one of the following: DRM, epidemiology, costs, treatment options, clini-
cal outcomes. Results: Database search yielded 12,570 articles and 60 additional 
articles were identified via secondary hand searches. Of the 167 eligible articles; 42 
provided information on DRM definition, screening and treatment guidelines, 29 
on epidemiological data, 38 on clinical outcomes, and 17 on cost. Most screening 
tools incorporated recent weight loss, food intake, and disease severity. Prevalence 
estimates varied greatly within and by region; US (1%-54%), Europe (2.5%-86%), Asia 
(12%-55.2%), Latin America (34.8% - 78.8%), and Canada (31%-69%). Malnourished 
patients compared to well-nourished patients experienced longer hospital stay 
(additional days between 1.6 and 6.6) and higher costs per hospital stay (19%-54.9%). 
Malnourished patients in the US, Europe, Asia, and Latin America incurred costs 
between USD$21900-$66700, EUR€ 4890-€ 12237, SGD$4606, and BRL$3807, respec-
tively. ConClusions: DRM assessment and prevalence varies greatly due to the 
disparate malnutrition definition and screening criteria. Broad estimates of the 
financial burden exist in some countries however the validity of some estimates is 
poor and lack generalizability. Health economic research is needed to address the 
present scarcity of data necessary to fully characterize the financial burden of DRM.
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objeCtives: To determine the types of medication-related interventions, and 
attendant resolution rates associated with telephonic versus in-person medica-
tion therapy management (MTM) consults. Methods: A retrospective review of 
electronic medical records and prescription claims data was conducted. Patients 
with one consult between January 1st and May 31st2013 were included; the date of 
the consult was defined as the index date. Data regarding intervention resolution 
was collected within 6 months post index. Inclusion criteria: one MTM consult with 
a Scott & White pharmacist within the study period. Exclusion criteria: multiple 
consults within the study period. Interventions regarding non-prescription medi-
cations and medication coupon use were excluded from outcomes reporting. Each 
intervention was grouped into 1 of 5 categories: cost, safety and efficacy, preventa-
tive therapy, education, and vaccination. Chi squared analyses were used to detect 
significant differences at a p-value of 0.05. Results: Forty-three patients and 105 
patients were identified in the in-person and telephonic consult groups respectively. 
Among patients who received in-person consults, the majority of interventions were 
related to education (35%), cost (26%), and safety and efficacy (22%). Interventions 
related to education (21%), cost (33%), and safety and efficacy (25%) also comprised 
the majority of interventions in the telephonic consult setting. There were no signifi-
cant differences detected, between groups, in the types of interventions occurring 
in each setting. The acceptance rate of vaccine related interventions was greater 
in the in-person consult group when compared to the telephonic consult group 
(p= 0.02). There were no significant differences observed in the acceptance rates of 
interventions regarding cost, safety and efficacy, preventative therapy, and educa-
tion. ConClusions: While there were no statistically significant differences in 
acceptance rates associated with education, cost, and safety and efficacy, the results 
of this study suggest that interventions related to vaccination are more likely to be 
accepted when made in person.
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objeCtives: Sugammadex significantly shortens time and variability to recov-
ery from neuromuscular blockade (NMB) compared to neostigmine. Our objective 
is to explore the potential impact on operating room (OR) efficiency with use 
of sugammadex versus neostigmine for NMB reversal in Canada. Methods: A 
discrete event simulation (DES) model was developed to compare two OR suites, 
one using neostigmine and the other sugammadex. The same OR parameters, 
including OR day start and end time, time to start first surgery, and time between 
surgeries, are shared by the two ORs. The same surgeries are scheduled in the 
two ORs. In the OR using sugammadex, a reduction in OR time per procedure is 
applied. Base-case time reductions (17.1 minutes) are derived from a head-to-head 
randomized controlled trial where tracheal extubation occurs when the patient 
achieves the recommended recovery of a Train-of-Four (TOF) ratio ≥ 0.9. In real-
life, patients, however, may be extubated irrespective of recovering to a TOF ratio 
≥ 0.9; therefore, exploratory analyses were also conducted with a range of values 
(0 to 25 minute reductions) for potential time savings with sugammadex. The 
model can also consider reduction in variability of OR time with sugammadex 
use. During each run, the model calculates a value for each parameter according 
to a statistical distribution. Results: For the base-case analysis, the primary 
